Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0150 • ACR Convergence 2021
Clinical Characteristics and Quantitative CT Findings in Connective Tissue Disease-Associated Interstitial Lung Disease
Sirus Jesudasen¹, Badar Patel², Kristin D'Silva¹, Pietro Nardelli², Ruben San José Estépar², George Washko², Raúl San José Estépar², Farbod Rahaghi² and Sydney Montesi¹, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Precapillary Pulmonary Hypertension (PPH) is a known complication of connective tissue disease-associated interstitial lung disease (CTD-ILD) but at present requires right heart catheterization (RHC)…
Abstract Number: 0618 • ACR Convergence 2021
Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
Alice Fike¹, Omer Pamuk², Yiming Luo³, Jun Chu⁴, Yanira Ruiz-Perdomo³, Sarfaraz Hasni³, Pravitt Gourh³ and James Katz⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²NIH/NIAMS, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The longitudinal experience of COVID-19 illness in patients with rheumatic diseases is emerging. Reports from the general population have described post-acute sequelae of SARS-CoV-2…
Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³, Ricardo Blanco⁴ and Marcos Lopez-Hoyos⁵, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
Abstract Number: 1526 • ACR Convergence 2021
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Chathura Wijewardena¹, Paramarajan Pirinavan¹, Sandy Nasr¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α (TNF-α) inhibitor therapy has been widely used worldwide as a potent immunosuppressant for a variety of rheumatological diseases. Induction of…
Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0846 • ACR Convergence 2020
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Ram Singh¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…
Abstract Number: 1248 • ACR Convergence 2020
Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort
Rana Mongroo¹, Samira Chowdhury² and Steven Carsons², ¹Mount Sinai South Nassau Hospital, Mineola, NY, ²NYU Winthrop Hospital, Mineola, NY
Background/Purpose: Sjögren’s disease (SS) is characterized by the presence of antibodies against protein-small RNP complexes designated Ro/SSA and La/SSB. Both are included in the 2002…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 0293 • ACR Convergence 2020
Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus
Robert Clancy¹, Miranda Marion², Peter Izmirly³, Mala Masson⁴, Hannah Ainsworth², Timothy Howard⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU School of Medicine, New York, ²Wake Forest School of Medicine, Winston-Salem, ³Department of Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, ⁵Wake Forest School of Medicine, Winston-Salem, NC, ⁶Department of Medicine, NYU School of Medicine, New York, NY, ⁷Wake Forest School of Medicine, Winston Salem, NC
Background/Purpose: Anti-Ro autoantibody production often precedes the development of systemic lupus erythematosus (SLE) or Sjögren’s syndrome (SS) by years. Anti-Ro+ mothers of children with manifestations…
Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
Abstract Number: 1250 • ACR Convergence 2020
Early Sjögren Antibodies: Potential Biomarker for Abnormal Minor Labial Salivary Gland Biopsy in Juvenile Sjögren’s Syndrome
Akaluck Thatayatikom¹, Sthorn Thatayatikom¹, Indraneel Bhattacharyya², Melissa Elder¹, Renee Modica¹ and Seunghee Cha², ¹Department of Pediatrics, University of Florida, Gainesville, FL, ²College of Dentistry, University of Florida, Gainesville, FL
Background/Purpose: Juvenile Sjögren’s Syndrome (jSS) is a perplexing systemic autoimmune disease in children presenting with positive autoantibodies, glandular, and/ or extraglandular symptoms. In pediatric practice,…
Abstract Number: 1524 • ACR Convergence 2020
Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice
Xiaoyang Yue¹, Frank Petersen¹, Xinhua Yu¹, Gabriela Riemekasten², Peter Lamprecht³, Antje Müller³ and Junping Yin⁴, ¹Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Borstel, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany, ³University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁴1 Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL),, Borstel, Germany
Background/Purpose: To explore the pathogenic potential of lymphocytes in systemic sclerosis (SSc) and granulomatosis with polyangiitis (GPA), a humanized mouse model was generated by transferring…
Abstract Number: 0296 • ACR Convergence 2020
Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
Carolina Munoz-grajales¹, Stephenie Prokopec², Dennisse Bonilla³, Earl D. Silverman⁴, Sindhu Johnson³, Arthur Bookman⁵, Zahi Touma⁶, Zareen Ahmad⁷, Linda Hiraki⁸, Paul Boutros⁹, Andrzej Chruscinski¹⁰ and Joan Wither³, ¹University of Toronto, Toronto, Canada, ²Ontario Institute for Cancer Research, Toronto, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network; 8Department of Medicine, University of Toronto; Division of Rheumatology, Toronto, Canada, ⁶University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, ⁷Department of Medicine, University of Toronto; Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Department of Medicine, University of Toronto, Toronto, Canada, ⁹Department of Immunology, University of Toronto; Department of Medical Biophysics, University of Toronto; Department of Pharmacology and Toxicology, University of Toronto; Department of Human Genetics, University of California; Department of Urology, University of California; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California; Institute for Precision Health, University of California; Jonsson Comprehensive Cancer Centre, University of California, Toronto, Canada, ¹⁰Multi-Organ Transplant Program, University Health Network, Toronto, Canada
Background/Purpose: Within the Anti-Nuclear Antibody (ANA) associated Systemic Autoimmune Rheumatic Diseases (SARD), such as Systemic Lupus Erythematous (SLE), Sjögren’s Syndrome (SS), and Systemic Sclerosis (SSc),…
Abstract Number: 0916 • ACR Convergence 2020
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Fiza Ahmed¹, Svetlana Nihtyanova¹, Stamatia Chatzinikolaou², Voon Ong¹, Charles Murray² and Christopher Denton³, ¹Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ²Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
Abstract Number: 1261 • ACR Convergence 2020
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].